SPYRAL HTN-ON MED RANDOMIZED CLINICAL TRIAL

HTN-ON MED TRIAL DESIGN

Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)

PRIMARY OUTCOME MEASURES

Decorative image

Acute and chronic safety by evaluating incidence of major adverse events from baseline to one month post-procedure or six months for new renal artery stenosis
 

Decorative image

Change in systolic blood pressure as measured by 24-hour ambulatory blood pressure monitoring (ABPM) from baseline to six months post-procedure
 

Diagram covering pathway for high blood pressure (HBP) screening and renal denervation (RDN) enrollment as part of the SPYRAL HTN-ON MED Trial.

DESIGN DETAILS

  • Estimated Enrollment: 340 participants
  • Study Type: Interventional (Clinical Trial)
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Treatment
  • Actual Study Start Date: July 2015

This trial is currently recruiting. More details are available at SpyralHTNtrials.com

REGISTER FOR CLINICAL TRIAL UPDATES

Register to receive information about the latest Medtronic RDN clinical trial data.

SIGN UP FOR EMAIL

EXPLORE RDN FURTHER

Get the latest news about RDN and see if there is an upcoming event near you.

VISIT NEWS AND EVENTS
Medtronic branded color blocks

Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorization for use.

CAUTION.  Investigational device. Limited by U.S. law to investigational use.

1

Measurement started after witnessed drug ingestion.

2

Drug testing.